| Name | Title | Contact Details |
|---|
Kedalion Therapeutics is a clinical-stage, venture-funded ophthalmic drug company based in Menlo Park, CA. Kedalions AcuStream technology delivers topical drugs to the eye in a precise and accurate manner that enables comparable efficacy with an 80% reduction in dose compared to standard drops, and a significantly improved side effect profile along with patient comfort and convenience following self-administration.
Ōmcare is a digital health company that aims to change the way the world cares by extending the reach of caregivers, increasing medication adherence, and improving treatment outcomes through the power of remote care and two-way video technology. By partnering with pharmacies, payers, providers, and family caregivers, Ōmcare strives to help people live healthier, more vibrant, independent lives and reduce healthcare cost. Ōmcare`s first product is called the Ōmcare Home Health Hub - a web-enabled platform that dispenses medication and provides two-way, audiovisual confirmation of medication adherence while facilitating social interaction and remote telehealth care. Ōmcare exists due to the rapidly aging population; high rate of medication nonadherence; a shortage of family and professional caregivers; continued increase in health care costs; consumer preference for in-home care and aging in place; changing reimbursement for home care services; and advancements remote monitoring and wearable technology.
Arizona Foundation for Medical Care is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BERG is a Boston-based biopharma company focused on taking a bold “back to biology” approach to therapeutic discovery using its unique AI-based Interrogative Biology® platform. This platform combines patient biology and AI-based analytics to engage the differences between healthy and disease environments. The patient’s own biology drives the platform’s results and guides us in the discovery and development of drugs, diagnostics and healthcare applications. Our platform utilizes patient population health data to bring actionable Patient IntelligenceTM to precision medicine applications. For patients this means faster discovery and development of treatments, more effective precision treatments for individuals as well as a reduction in costs to our healthcare systems. BERG has a robust product portfolio in oncology, endocrinology and neurology with mature assets in oncology entering mid and late stage trials. BERG is committed to improving the lives of patients through precision medicine made possible by our innovative platforms.
Celator Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is transforming the science of combination therapy and developing products to improve outcomes for patients with cancer. The Company is working to establish a new treatment paradigm in which rationally-designed, fully-integrated combination products replace combination regimens of individual agents. Celator`s proprietary technology platform, CombiPlex®, identifies the most effective synergistic ratio of the component drugs, optimizes the pharmacology of the drug combination prior to human clinical trials, allows simultaneous administration of the components as a single product and maintains the synergistic ratio of the components after administration thereby exposing tumor cells to the right amounts of drug for the right length of time.